USPTO serial 79301765
GALAPAGOS. PIONEERING FOR PATIENTS.
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jan 11, 2022
- Examiner
- DYER, ERIN ZASKODA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with GALAPAGOS. PIONEERING FOR PATIENTS.?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,097*
Plus Government fees of $975
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alexandra MacKay
Alexandra MacKay Stites & Harbison, PLLC401 Commerce StreetSuite 800Nashville, TN 37219Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 041 | Education services, namely, organizing and conducting conferences, seminars, workshops and classes in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals for the treatment of medical disorders and dissemination of materials in connection therewith; provision of training, namely, provision of training in the fields of chemistry, medicinal chemistry, biochemistry, biotechnology, drug discovery, drug development and pharmaceuticals for the treatment of medical disorders and dissemination of materials in connection therewith | ACTIVE | — |
| 042 | Medical and scientific research services; industrial research services in the field of assay development, target discovery and validation, drug development, and medicinal chemistry; pharmaceutical and biopharmaceutical research and development services; medical and scientific research, namely, the examination and testing of genes; development, laboratory analysis, and testing of pharmaceutical and biopharmaceutical semi-finished products for use in medicaments; development, laboratory analysis, and testing of medicaments; the development of clinical assays, cellular tests, testing kits, diagnostic kits, and companion diagnostics for evaluating pharmaceutical and biopharmaceutical products of others; development of computer databases in the medical, pharmaceutical and biopharmaceutical fields; development of computer data banks containing information concerning gene expression and gene therapy; pharmaceutical drug development services | ACTIVE | — |
| 044 | Medical services; medical and pharmaceutical advisory and consultancy services; gene bank services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Galapagos N.V.
- Other trademarks owned by Galapagos N.V.
- Other trademarks owned by Galapagos N.V.
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named GALAPAGOS. PIONEERING FOR PATIENTS.
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Aug 1, 2022 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 29, 2022 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Jun 29, 2022 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Apr 11, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 11, 2022 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 26, 2021 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 26, 2021 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 6, 2021 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 17, 2021 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 31, 2021 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 30, 2021 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 30, 2021 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 22, 2021 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 1, 2021 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 1, 2021 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 24, 2021 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 23, 2021 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 9, 2021 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 19, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jan 15, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jan 14, 2021 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Jan 7, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |